ALITRETINOIN: 80 Adverse Event Reports & Safety Profile
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
Drug Class: Retinoid [EPC] · Route: TOPICAL · Manufacturer: Advanz Pharma (US) Corp. · FDA Application: 020886 · HUMAN PRESCRIPTION DRUG · FDA Label: Available
First Report: 20170101 · Latest Report: 20220526
What Are the Most Common ALITRETINOIN Side Effects?
All ALITRETINOIN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 20 | 25.0% | 0 | 0 |
| Breast cancer | 14 | 17.5% | 0 | 0 |
| Drug intolerance | 12 | 15.0% | 0 | 0 |
| Off label use | 12 | 15.0% | 0 | 1 |
| Pruritus | 12 | 15.0% | 0 | 0 |
| Hepatic enzyme increased | 11 | 13.8% | 0 | 0 |
| Blister | 9 | 11.3% | 0 | 0 |
| Pain in extremity | 9 | 11.3% | 0 | 0 |
| Psoriatic arthropathy | 9 | 11.3% | 0 | 0 |
| Skin injury | 9 | 11.3% | 0 | 0 |
| Abdominal discomfort | 8 | 10.0% | 0 | 0 |
| Treatment failure | 8 | 10.0% | 0 | 0 |
| C-reactive protein increased | 7 | 8.8% | 0 | 0 |
| Hypercholesterolaemia | 7 | 8.8% | 0 | 1 |
| Xerophthalmia | 7 | 8.8% | 0 | 0 |
| Hypertriglyceridaemia | 6 | 7.5% | 0 | 1 |
| Psoriasis | 6 | 7.5% | 0 | 1 |
| Product use in unapproved indication | 5 | 6.3% | 1 | 1 |
Who Reports ALITRETINOIN Side Effects? Age & Gender Data
Gender: 67.4% female, 32.6% male. Average age: 58.1 years. Most reports from: FR. View detailed demographics →
Is ALITRETINOIN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2017 | 4 | 0 | 0 |
| 2019 | 15 | 0 | 0 |
| 2020 | 4 | 0 | 1 |
| 2021 | 3 | 0 | 1 |
| 2022 | 1 | 1 | 1 |
What Is ALITRETINOIN Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 20 |
| Pityriasis rubra pilaris | 14 |
| Neurodermatitis | 11 |
| Pustular psoriasis | 9 |
| Psoriasis | 6 |
| Kaposi's sarcoma | 5 |
Other Drugs in Same Class: Retinoid [EPC]
Official FDA Label for ALITRETINOIN
Official prescribing information from the FDA-approved drug label.
Drug Description
PANRETIN GEL is a retinoid. PANRETIN GEL 0.1% contains alitretinoin and is intended for topical application only. The chemical name is (2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, also known as 9-cis-retinoic acid. Chemically, alitretinoin is related to vitamin A. It is a yellow powder with a molecular weight of 300.44 and a molecular formula of C 20 H 28 O 2 . It is slightly soluble in ethanol (7.01 mg/g at 25℃) and insoluble in water. The structural formula of alitretinoin is as follows: PANRETIN GEL is a clear, yellow gel containing 0.1% (w/w) alitretinoin. Each gram of PANRETIN GEL contains 1 mg alitretinoin. PANRETIN GEL contains the following inactive ingredients: butylated hydroxytoluene NF, dehydrated alcohol USP 92%, hydroxypropyl cellulose NF, and polyethylene glycol 400 NF. alitretinion
FDA Approved Uses (Indications)
AND USAGE
1.1 Kaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS). Limitations of Use: PANRETIN GEL is not indicated when systemic anti-KS therapy is required (including more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement) <span class="opacity-50 text-xs">[see Clinical Studies ( 14.1 )]</span> . PANRETIN GEL is a retinoid indicated for the topical treatment of cutaneous lesions in adults with AIDS-related Kaposi’s sarcoma (KS). Limitations of Use : PANRETIN GEL is not indicated when systemic anti-Kaposi’s sarcoma therapy is required.
Dosage & Administration
AND ADMINISTRATION PANRETIN GEL is for topical use only. Do not use occlusive dressings with PANRETIN GEL. Apply PANRETIN GEL twice daily to coat the entire cutaneous Kaposi sarcoma lesions. Gradually increase the application frequency up to four (4) times a day as tolerated. Continue PANRETIN GEL as long as patient is deriving benefit. Reduce application frequency for application site toxicity. Interrupt treatment for severe irritation; may resume at a reduced application frequency once symptoms improve. Avoid application of gel to normal skin and do not apply on or near mucosal surfaces. Wash hands after application unless gel is applied to Kaposi sarcoma lesions on the hands. Allow gel to dry for three to five minutes before covering with clothing.
- Apply to the affected lesions twice daily; increase to 4 times daily as tolerated. ( 2 )
- For topical use only. ( 2 )
Contraindications
PANRETIN GEL is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product. Hypersensitivity to retinoids or any component of PANRETIN GEL ( 4 )
Known Adverse Reactions
REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:
- Photosensitivity [see Warnings and Precautions ( 5.2 )] Most common adverse reactions (> 5%) at the application site are rash, pain, paresthesia, pruritis, exfoliative dermatitis, edema, and skin disorders. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Advanz Pharma (US) Corp. at 1-877-370-1142 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of PANRETIN GEL was assessed in two multicenter, prospective, randomized, double-blind, vehicle-controlled trials (Trial 1 and Trial 2) in patients with cutaneous lesions of AIDS-related KS <span class="opacity-50 text-xs">[see Clinical Studies ( 14.1 )]</span> . In a pooled analysis of both trials, the most common adverse reactions in ≥ 5% of patients were rash, pain, paresthesia, pruritis, exfoliative dermatitis, edema, and skin disorder.
In Trial
1, severe local skin adverse reactions (erythema and edema with or without vesiculation) occurred in 10% of patients during the first 12 weeks of treatment (versus 0% in the vehicle control). Adverse reactions led to withdrawal from the study in 7% of patients.
In Trial
2, severe local skin adverse reactions (erythema and edema with or without vesiculation) occurred in 6% of patients during the first 12 weeks of treatment (versus 0% in the vehicle control) and 1 patient withdrew due to severe skin irritation.
Table
1 lists the most common application site adverse reactions that occurred in a least 5% of patients during the double-blind phase who received PANRETIN GEL in either of the two controlled studies. TABLE 1: Adverse Reactions at Application Site in Trial 1 and 2 in ≥ 5% of Patients Treated with PANRETIN GEL A dverse Event Term Trial 1 Trial 2 PANRETIN GEL N=134 % Vehicle Gel N=134 % PANRETIN GEL N=36 % Vehicle Gel N=46 % Rash 1 77 11 25 4 Pain 2 34 7 0 4 Pruritus 3 11 4 8 4 Exfoliative dermatitis 4 9 2 3 0 Skin disorder 5 8 1 0 0 Edema 6 8 3 3 0 Parethesia 7 3 0 22 7 Includes Investigator terms: 1 Erythema, scaling, irritation, redness, rash, dermatitis 2 Burning, pain 3 Itching, pruritus 4 Flaking, peeling, desquamation, exfoliation 5 Excoriation, cracking, scab, crusting, drainage, eschar, fissure or oozing 6 Edema, swelling, inflammation 7 Stinging, tingling
Warnings
AND PRECAUTIONS
- Embryo-Fetal Toxicity : Can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception. ( 5.1 . 8.1 , 8.3 )
- Photosensitivity : Minimize exposure to sunlight and sunlamps. ( 5.2 )
- DEET toxicity : Do not use DEET-containing products ( 5.3 )